-
2023-503865-48-00
4
2024-02-16
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
-
2022-502831-20-00
1
2024-02-15
Male and female adult patients with relapsed Multiple Myeloma or Diffu
-
2022-500531-36-00
4
2024-02-02
Type 1 diabetes mellitus
-
2022-502113-28-00
5
2024-02-01
Follicular lymphoma
-
2023-503938-52-00
4
2024-01-26
Progressive Glioblastoma
-
2023-504141-31-00
4
2024-01-17
Metastatic HR positive, HER2 negative breast cancer
-
2023-504322-19-00
5
2024-01-10
Patients in the intensive care unit on ventilation with pneumonia and
-
2022-503114-23-00
3
2023-12-19
Breast Cancer
-
2022-501941-63-00
7
2023-12-13
Multiple myeloma
-
2023-504351-26-01
11
2023-12-06
Pulmonary arterial hypertension (group I)
-
2023-503224-66-00
5
2023-10-31
Atrial Fibrillation
-
2023-503582-35-00
6
2023-10-26
Staphylococcus aureus bacteremia
-
2024-512179-11-00
6
2023-10-26
Patients with prediabetes (defined as impaired fasting glucose [IFG]
a
-
2023-503558-10-00
5
2023-10-13
oligometastatic pancreatic cancer
-
2022-502160-20-00
5
2023-10-02
Idiopathic Immune Complex Mediated Membranoproliferative Glomeruloneph
-
2022-502157-33-00
7
2023-09-18
B-Cell Malignancies
-
2022-502732-39-00
10
2023-09-01
Previously treated non-ocular advanced melanoma
-
2022-503133-54-00
7
2023-08-09
Solid Tumors
-
2024-512320-11-00
5
2023-08-09
Primary diffuse large B-cell lymphoma of the central nervous system
(P
-
2022-501797-19-00
1
2023-07-13
Acute Myeloid Leukemia (AML)
-
2024-517966-40-00
4
2023-07-13
Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
-
2024-514022-23-00
4
2023-06-23
Early breast cancer
-
2024-513929-23-00
10
2023-05-26
Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Seve
-
2022-500699-76-00
5
2023-05-18
Active Systemic Lupus Erythematosus (SLE)